Selected for the Global Physician Scientist training program
[by Yu, Suin] Samsung Medical Center has stepped up to tackle ‘central nervous system (CNS) inflammatory diseases,’ conditions that penetrate the blood-brain barrier (BBB), attack the brain and spinal cord, and result in permanent disability. On September 25, Samsung Medical Center announced that it has been selected for the Ministry of Health and Welfare’s ‘Global Physician-Scientist Collaboration Project’ under the ‘Global Physician-Scientist Training Program,’ in collaboration with the University of Colorado, the Korea Institute of Science and Technology (KIST), and the Sungkyunkwan University Industry-Academic Cooperation Foundation.
The selected research topic is ‘Next-Generation Central Nervous System 바카라 카지노s Using Antibody Platforms and Lymphatic Engineering.’ The project will be supported with a total research grant of KRW 6.625 billion (approximately USD 4.6 million) over a period of four years and five months, from August 2025 to December 2029.
The study is being spearheaded by Samsung Medical Center, led by Professors Park Kyung-ah and Kim Jae-ryung of the Department of Ophthalmology, Professor Min Ju-hong of the Department of Neurology, and Professor Ryu Gwang-hui of the Department of Otorhinolaryngology. Collaborating institutions include the Korea Institute of Science and Technology (KIST), the College of Pharmacy at Sungkyunkwan University, and the Department of Neurology at the University of Colorado School of Medicine as co-investigators. Together, the research team is pursuing the development of novel treatments CNS 바카라 카지노 diseases, affecting areas such as the optic nerve, including multiple sclerosis, neuromyelitis optica (NMO), and MOG antibody disease.
CNS 바카라 카지노 diseases are characterized by frequent relapses and treatment challenges, imposing a heavy burden on patients and often demonstrating high refractory rates to existing treatments, underscoring the need for new treatment options. In particular, neuromyelitis optica and MOG antibody disease are rare, incurable conditions with few or no approved therapies, highlighting the urgent demand for developing novel therapeutics.
To address this unmet 바카라 카지노 need, the research team has turned its attention to the lymphatic vessels of the central nervous system. These vessels are critical for suppressing neuroinflammation by draining cerebrospinal fluid, removing waste, and modulating immune responses. More recently, lymphatic vessels surrounding the optic nerve have been identified as key regulators of inflammation through their interaction with the glymphatic system, an insight now emerging as a promising driver in the development of new-generation therapies.
The research team expects this study to pave the way for fundamental treatments for 바카라 카지노 neurological diseases by regulating lymphatic function. Their strategy includes developing customized antibodies targeting specific antigens and leveraging an antibody platform to establish Korea's first animal model for central nervous system 바카라 카지노 disorders, as well as the world's first animal model based on lymphatic function regulation. In addition, the team plans to build optic nerve organoids to cross-validate the efficacy and safety of therapeutic candidates and to advance personalized treatment strategies through artificial intelligence (AI)-driven multi-omics analysis.
Professor Park Kyung-ah of the Department of Ophthalmology at Samsung Medical Center, who leads the study, stated, “This research represents a challenging yet important step toward unlocking the possibility of fundamental treatments for central nervous system 바카라 카지노 disease, with a focus on the role of CNS lymphatic vessels.” She added, “By working in collaboration with world-class researchers, we are committed to bringing new hope to patients battling intractable neurological conditions while strengthening our hospital’s position as a global leader in medical technique innovation.”